From: Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
Case | Age (years) | Sex | Eye | Medical history | Lesion location | Fovea | Anti-VEGF injection | Follow-up (months) | BCVA | CMT(μm) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
baseline | final | baseline | final | |||||||||
1 | 69 | female | left | HT | supra-temporal | IRH, SRD | ranibizumab # 2 | 12 | 20/70 | 20/30 | 392 | 205 |
2 | 76 | female | right | HT | infra-temporal | IRH, SRD | ranibizumab #2 | 12 | 20/200 | 20/50 | 465 | 183 |
3 | 62 | female | left | HT | infra-temporal | PRH | conbercept #1 | 6 | CF | 20/40 | 799 | 313 |